NVO241227P78000
- 0.01
- 0.000.00%
Novo-Nordisk A/S Newsroom
Elon Musk Admits To Using Weight Loss Medication Criticized By RFK Jr, Says He Prefers Mounjaro Over Miracle Drug Ozempic
Behind the Scenes of Novo Nordisk's Latest Options Trends
Here's Why Novo Nordisk A/S (NVO) Slid in Q3
US MOVERS&SHAKERS Dec 23-Dec 27, 2024
3 Healthcare Stocks to Buy for a 2025 Rebound
Top Gap Ups and Downs on Thursday: TM, LI, KB and More
Novo-Nordisk A/S faces another blow: Musk shares a weight loss photo, claiming that using Eli Lilly and Co's weight loss drug is more effective than semaglutide.
On Christmas, Musk shared a photo and called himself the Ozempic Santa Claus, clarifying that he didn't mean the drug name Ozempic for semaglutide, but rather Eli Lilly and Co's competitor Mounjaro. He also mentioned that "high doses" of Ozempic would make him fart and burp, adding that "Mounjaro seems to have fewer side effects and is more effective."
Novo-Nordisk A/S Options Spot-On: On December 26th, 96,143 Contracts Were Traded, With 459.29K Open Interest
Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?
Musk revealed that he switched to using Eli Lilly and Co's weight loss medication: the effect is better than Novo-Nordisk A/S's competing products, with fewer side effects.
① The world's richest man Elon Musk confirmed on the Social Media platform X on Wednesday that he is using Eli Lilly and Co's Mounjaro for weight loss; ② Musk revealed that he initially tried using Novo-Nordisk A/S's Ozempic for weight loss, but switched to Mounjaro due to significant side effects.
Musk "endorses" Eli Lilly and Co (LLY.US) weight loss drug: Mounjaro has fewer side effects and better results.
On Wednesday, Musk posted on the X platform emphasizing that he prefers Eli Lilly and Co's product Mounjaro over Novo-Nordisk A/S's weight loss treatment Ozempic.
Elon Musk Says He Prefers Lilly's Mounjaro Over Novo's Ozempic
"Nuo Li" weight loss miracle drug mainstreaming brings new challenges in terms of applicability, medical insurance, and more.
GLP-1 is changing the way people view and treat obesity. These changes are happening so quickly that they may benefit many people, leading to new questions and ethical dilemmas for medical professionals, including who should receive medication treatment.
Jim Cramer Says Novo Nordisk A/S (NVO) Can't Exceed Eli Lilly
Novo Nordisk Is 'Losing Its Pep' in GLP-1 Race: BMO Analyst
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
Novo-Nordisk A/S Options Spot-On: On December 24th, 32,364 Contracts Were Traded, With 453.78K Open Interest
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
Novo Nordisk Shares Rally Despite Setback in Obesity Drug Trial Results